LONDON (Alliance News) - ValiRx PLC Thursday said the US patent for the novel cancer treatment being developed under a joint venture with Tangent Reprofiling Ltd has been approved and awarded.
The joint venture company, ValiSeek Ltd, has received notification from the US Patent Office that the patent for the treatment, named VAL401, has been approved.
The company said this patent grant significantly strengthens and validates the science, novelty and founding basis behind the VAL401 project and said it believes that the grant allowance provides a strong platform for the compound's future global commercialisation.
Valirx shares were up 14.1% to 0.240 pence per share late Thursday afternoon.
By Joshua Warner; joshuawarner@alliancenews.com; @JoshAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
ValiRx (VAL)